Mirvetuximab soravtansine

Mirvetuximab soravtansine is used to treat adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are no longer responding to platinum-based chemotherapy and have received 1 to 3 types of chemotherapy.

Your doctor will perform tests to ensure that mirvetuximab soravtansine is the right treatment for you.

Mirvetuximab soravtansine may also be used for purposes not listed in this medication guide.

Call your doctor right away if you have any eye issues, such as blurred vision, eye pain, or any new or worsening vision problems.

Tell your doctor if you have or have ever had:

• vision or eye problems; or
• liver problems.

May harm an unborn baby. Do not use if you are pregnant. Use effective birth control while using mirvetuximab soravtansine and for at least 7 months after your last dose. Tell your doctor if you become pregnant.

You may need to have a negative pregnancy test before starting this treatment.

Do not breastfeed while using mirvetuximab soravtansine, and for at least 1 month after your last dose.

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Mirvetuximab soravtansine may cause serious side effects. Call your doctor right away if you experience:

• dry eyes, sensitivity to light, blurred vision, eye pain, or new or worsening vision changes;
• cough, chest pain, trouble breathing, or shortness of breath; or
• numbness, tingling, or burning pain in your hands or feet.

Common side effects of mirvetuximab soravtansine may include:

• abnormal lab results;
• nausea, stomach pain, diarrhea, or constipation;
• fever, mouth sores, skin sores, sore throat, or cough; or
• pale skin, tiredness, feeling light-headed or short of breath, or cold hands and feet.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Follow all directions on your prescription label and read all medication guides or instruction sheets.

Your doctor may change, delay, or permanently discontinue your treatment with mirvetuximab soravtansine if you have certain side effects.

Mirvetuximab soravtansine is usually given every 3 weeks as an infusion into your vein. Your doctor will decide how many cycles you need.

You may be given other medications to help prevent serious side effects or allergic reaction. Keep taking these medicines for as long as your doctor has prescribed.

You may need frequent vision exams.

Your doctor may prescribe eye drops before and during your treatment with mirvetuximab soravtansine. You should use these eye drops as directed by your doctor.

Call your doctor for instructions if you miss an appointment for your Mirvetuximab soravtansine injection.

In a medical setting, an overdose would be treated quickly.

Do not wear contact lenses while using mirvetuximab soravtansine unless your doctor tells you to.

Tell your doctor about all the medicines you are currently taking. Many drugs can impact mirvetuximab soravtansine, especially:

• nefazodone;
• cancer medicines--ceritinib, idelalisib, ribociclib, tucatinib;
• antibiotics--clarithromycin, telithromycin;
• antifungal medicines--itraconazole, ketoconazole, posaconazole, voriconazole; or
• antiviral medicines for HIV or hepatitis C--boceprevir, cobicistat, dasabuvir, elvitegravir, indinavir, lopinavir/ritonavir, nelfinavir, ombitasvir, paritaprevir, saquinavir, telaprevir, tipranavir.

This list is not complete, and many other drugs may affect mirvetuximab soravtansine. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are mentioned here.